Q2 INTERIM REPORT APRIL - JUNE 2022
READ MORE
Mentice acquires Ankyras solutions from Galgo Medical SL
READ MORE

Issuance of new shares in Mentice AB (publ) has been registered with the Swedish Companies Registration Office

Friday, December 4, 2020

Regarding the acquisition of the assets from Vascular Simulations Inc 571,974 shares have been issued at a subscription price of SEK 86.16 and regarding the acquisition of the assets from EQIP Inc, 9,469 shares have been issued at a subscription price of SEK 84.28.

The total number of shares in Mentice AB after registration with the Swedish Companies Registration Office amounts to 24,727,995 shares. Through the issuance of new shares, the share capital in Mentice AB has increased to SEK 1,236,399.75.

For details on the acquisitions, please refer to press releases dated October 1, 2020 and October 8, 2020.

For more information, please contact:
Göran Malmberg, CEO, Mentice
E-post: 
goran.malmberg@mentice.com

US Mobile. +1 (312) 860 5610

Sweden Mobile +46 (0) 703 09 22 22

About Mentice

Mentice is the world leader in software and hardware simulation solutions for endovascular therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular and peripheral interventions are just some of the clinical areas covered by our solutions. More information on www.mentice.com

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC

Certified Adviser| FNCA Sweden AB, phone +46 8 528 00 399

DELÅRSRAPPORT Q2 APRIL - JUNI 2022
LÄS MER
Mentice förvärvar Ankyras från det spanska företaget Galgo Medical S.L.
LÄS MER

Issuance of new shares in Mentice AB (publ) has been registered with the Swedish Companies Registration Office

Friday, December 4, 2020

Regarding the acquisition of the assets from Vascular Simulations Inc 571,974 shares have been issued at a subscription price of SEK 86.16 and regarding the acquisition of the assets from EQIP Inc, 9,469 shares have been issued at a subscription price of SEK 84.28.

The total number of shares in Mentice AB after registration with the Swedish Companies Registration Office amounts to 24,727,995 shares. Through the issuance of new shares, the share capital in Mentice AB has increased to SEK 1,236,399.75.

For details on the acquisitions, please refer to press releases dated October 1, 2020 and October 8, 2020.

For more information, please contact:
Göran Malmberg, CEO, Mentice
E-post: 
goran.malmberg@mentice.com

US Mobile. +1 (312) 860 5610

Sweden Mobile +46 (0) 703 09 22 22

About Mentice

Mentice is the world leader in software and hardware simulation solutions for endovascular therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular and peripheral interventions are just some of the clinical areas covered by our solutions. More information on www.mentice.com

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC

Certified Adviser| FNCA Sweden AB, phone +46 8 528 00 399